CDKN1B and intrahepatic cholangiocarcinoma: The decreased expression of CDKN1B then promotes tumourigenesis by accelerating the cell cycle and further desensitises ICC to cisplatin treatment by decreasing DNA damage and inhibiting apoptosis.